Hamza Hashmi: A very Detailed and Helpful Data for QOL and Informed Consent
Hamza Hashmi, Myeloma and Cellular Therapy Physician at Memorial Sloan Kettering Cancer Centre, shared a post on X by Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, adding:
“About 30% of the Multiple Myeloma patients had to stop reading/driving 3 months into treatment and almost everyone was able to resume these activities within a month with only one such occurrence likely due to dose modification. This is very detailed and helpful data for QOL and informed consent.”
Quoting Rahul Banerjee‘s post:
“Great Blood Advances paper by Maria-Victoria Mateos, Meletios Athanasios Dimopoulos et al: pooled data for dose mods from DREAMM-7 and -8.
With bela-maf in Multiple Myeloma, dose de-escalations are not the exception… they are the norm!
Over 70% of patients with responses had ≥3 separate dose interruptions in both trials.”
You can read featured post Hamza Hashmi and Rahul Banerjee on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023